Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer

Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in “castration syndrome”, a constellation of...

Descripción completa

Detalles Bibliográficos
Autor principal: Ali Shah, Syed Imran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418092/
https://www.ncbi.nlm.nih.gov/pubmed/25992351
http://dx.doi.org/10.4103/2278-330X.155699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418092/
https://www.ncbi.nlm.nih.gov/pubmed/25992351
http://dx.doi.org/10.4103/2278-330X.155699

Ejemplares similares